Pertussis cost-effectiveness of therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2] Luke Rusowicz-Orazem, B.S.
Cost Effectiveness of Therapy
Cost Effectiveness of Therapy
- Given the morbidity of of Pertussis, the cost-effectiveness of treatment is substantial.
- A retrospective assessment of medical costs of confirmed pertussis in 936 adults in Massachusetts during 1998 to 2000, and a prospective assessment of nonmedical costs in 203 adults during 2001 to 2003 indicated that the mean medical and nonmedical cost per case was $326 and $447, respectively, for a societal cost of $773.[1]
- If the cost of antimicrobials to treat contacts and the cost of personal time were included, the societal cost could be as high as $1,952 per adult case.[1]
Cost Effectiveness of Vaccination
Cost Effectiveness of Vaccination
- Cost-benefit and cost-effectiveness analyses of adult Tdap vaccination have varied in their results. When discrepancies in the models were addressed, an adult Tdap vaccination program was cost-effective when incidence of pertussis exceeded 120 cases per 100,000 population, using a benchmark of $50,000 per quality-adjusted life year saved. [2]
References
References
- ↑ 1.0 1.1 “National Guideline Clearinghouse | Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP)”.
- ↑ Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, Schauer S, Lieu TA (2007). “Cost effectiveness of pertussis vaccination in adults”. Am J Prev Med. 32 (3): 186–193. doi:10.1016/j.amepre.2006.10.016. PMID 17296470.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH